{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-060937","form_type":"8-K","ticker":null,"cik":"0001769759","company_name":"Monogram Technologies Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.983740+00:00","generated_at":"2026-06-02T01:03:20.754265+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monogram Orthopaedics Q1 net loss $3.5M; 510(k) submission on track for H2 2024","bullets":["Net loss $3.5M in Q1 2024 vs $3.9M prior year; cash $10.1M at Mar 31.","Verification & validation testing expected largely complete in Q2 2024.","FDA 510(k) submission for mBôs TKA system planned for second half of 2024.","Engaged contract research organization for OUS clinical trial activities.","R&D expenses $2.4M, up from $1.9M, driven by V&V and mVision development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-060937","json":"https://secwatch.observer/filing/0001104659-24-060937.json","markdown":"https://secwatch.observer/filing/0001104659-24-060937.md","text":"https://secwatch.observer/filing/0001104659-24-060937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1769759/000110465924060937/0001104659-24-060937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1769759/000110465924060937/tm2414401d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:03:20.754265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ea9b79369341f38206a4db720952315bf78f3a1","claim":"Monogram Technologies Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $3.5 million.","evidence_excerpt":"On May 14, 2024, Monogram Orthopaedics Inc., a Delaware corporation (the “Company”) issued a press release announcing, among other things, its financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769759/000110465924060937/0001104659-24-060937-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $3.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}